American Journal of Ophthalmology
Volume 148, Issue 6 , Pages 883-889 , December 2009

Intravitreous Vascular Endothelial Growth Factor and Hypoxia-Inducible Factor 1a in Patients With Proliferative Diabetic Retinopathy

  • Xiaoqin Wang

      Affiliations

    • Department of Ophthalmology, Southwest Eye Hospital, Southwest Hospital, Third Military Medical University, Chongqing, China
    • ,
  • Guibo Wang

      Affiliations

    • Department of Infectious Diseases, Southwest Hospital, Third Military Medical University, Chongqing, China
    • ,
  • Yi Wang

      Affiliations

    • Department of Ophthalmology, Southwest Eye Hospital, Southwest Hospital, Third Military Medical University, Chongqing, China
    • Corresponding Author InformationInquiries to Yi Wang, Southwest Hospital, Third Military Medical University, Chongqing 400038, China

,Accepted 5 July 2009.

References 

  1. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature. 2001;414:782–787
  2. Gunduz K, Bakri SJ. Management of proliferative diabetic retinopathy. Compr Ophthalmol Update. 2007;8:245–256
  3. Simó R, Carrasco E, García-Ramírez M, Hernández C. Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy. Curr Diabetes Rev. 2006;2:71–98
  4. Churchill AJ, Carter JG, Ramsden C, et al. VEGF polymorphisms are associated with severity of diabetic retinopathy. Invest Ophthalmol Vis Sci. 2008;49:3611–3616
  5. Kakehashi A, Inoda S, Mameuda C, et al. Relationship among VEGF, VEGF receptor, AGEs, and macrophages in proliferative diabetic retinopathy. Diabetes Res Clin Pract. 2008;79:438–445
  6. Errera FI, Canani LH, Silva ME, et al. Functional vascular endothelial growth factor-634G>C SNP is associated with proliferative diabetic retinopathy: a case-control study in a Brazilian population of European ancestry. Diabetes Care. 2007;30:275–279
  7. Tsai DC, Charng MJ, Lee FL, Hsu WM, Chen SJ. Different plasma levels of vascular endothelial growth factor and nitric oxide between patients with choroidal and retinal neovascularization. Ophthalmologica. 2006;220:246–251
  8. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331:1480–1487
  9. Forsythe JA, Jiang BH, Iyer NV, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol. 1996;16:4604–4613
  10. Kim JH, Kim JH, Yu YS, Shin JY, Lee HY, Kim KW. Deguelin inhibits retinal neovascularization by down-regulation of HIF-1alpha in oxygen-induced retinopathy. J Cell Mol Med. 2008;12:2407–2415
  11. Van den Driesche S, Myers M, Gay E, Thong KJ, Duncan WC. HCG up-regulates hypoxia inducible factor-1 alpha in luteinized granulosa cells: implications for the hormonal regulation of vascular endothelial growth factor A in the human corpus luteum. Mol Hum Reprod. 2008;14:455–464
  12. Fukushima K, Murata M, Hachisuga M, et al. Hypoxia inducible factor 1 alpha regulates matrigel-induced endovascular differentiation under normoxia in a human extravillous trophoblast cell line. Placenta. 2008;29:324–331
  13. Tsuzuki Y, Fukumura D, Oosthuyse B, Koike C, Carmeliet P, Jain RK. Vascular endothelial growth factor (VEGF) modulation by targeting hypoxia-inducible factor-1alpha-→hypoxia response element→VEGF cascade differentially regulates vascular response and growth rate in tumors. Cancer Res. 2000;60:6248–6252
  14. Simo R, Vidal MT, Garcia-Arumi J, et al. Intravitreous hepatocyte growth factor in patients with proliferative diabetic retinopathy: a case-control study. Diabetes Res Clin Pract. 2006;71:36–44
  15. Simó R, Lecube A, Segura RMGarcía Arumí J, Hernández C. Free insulin growth factor-I and vascular endothelial growth factor in the vitreous fluid of patients with proliferative diabetic retinopathy. Am J Ophthalmol. 2002;134:376–382
  16. Kase S, Saito W, Ohgami K, et al. Expression of erythropoietin receptor in human epiretinal membrane of proliferative diabetic retinopathy. Br J Ophthalmol. 2007;91:1376–1378
  17. Funatsu H, Yamashita H, Nakanishi Y, Hori S. Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with proliferative diabetic retinopathy. Br J Ophthalmol. 2002;86:311–315
  18. Hernandez C, Lecube A, Castellanos JM, et al. Intravitreous leptin concentrations in patients with proliferative diabetic retinopathy. Retina. 2004;24:30–35
  19. Burgos R, Simo R, Audi L, et al. Vitreous levels of vascular endothelial growth factor are not influenced by its serum concentration in diabetic retinopathy. Diabetologia. 1997;40:1107–1109
  20. Hernández C, Burgos R, Cantón A, García-Arumí J, Segura RM, Simó R. Vitreous levels of vascular cell adhesion molecule and vascular endothelial growth factor in patients with proliferative diabetic retinopathy. Diabetes Care. 2001;24:516–521
  21. Funatsu H, Yamashita H, Noma H, et al. Aqueous humor levels of cytokines are related to vitreous levels and progression of diabetic retinopathy in diabetic patients. Graefes Arch Clin Exp Ophthalmol. 2005;243:3–8
  22. Pieh C, Agostini H, Buschbeck C, et al. VEGF-A, VEGFR-1, VEGFR-2, and Tie2 levels in plasma of premature infants: relationship to retinopathy of prematurity. Br J Ophthalmol. 2008;92:689–693

PII: S0002-9394(09)00503-0

doi: 10.1016/j.ajo.2009.07.007

American Journal of Ophthalmology
Volume 148, Issue 6 , Pages 883-889 , December 2009

Article Tools

* Image Usage & Resolution